title: Evaluation of low-dose cytarabine therapy in myelodysplastic syndromes.
abstract: Myelodysplastic syndromes (MDS) are a group of disorders characterised by progressive cytopenias and impaired maturation of haematopoietic cells. It carries a high mortality due to severe infections and/or bleeding, and transformation into acute myeloid leukaemia (AML). Its treatment is largely unsatisfactory except a few favorable reports with low-dose cytarabine therapy, which has recently created a widespread enthusiasm for its use.
authors.affiliation: Medicine Dpt., Hawari Hospital, Arab Medical University, Benghazi, Libya.
authors.forename: M
authors.initials: M
authors.lastname: el Mangoush
authors.forename: M K
authors.initials: MK
authors.lastname: Singh
authors.forename: S
authors.initials: S
authors.lastname: Kumar
authors.forename: M
authors.initials: M
authors.lastname: Korajkio
authors.forename: A
authors.initials: A
authors.lastname: Gamati
mesh_terms: D000368:Aged; D003561:Cytarabine / Q000008:administration & dosage*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*
chemical_list: D003561:Cytarabine